FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 59, Issue 4, 2012, Pages 662-667

  Kutny, Matthew A ^a,b   Moser, Barry K ^c   Laumann, Kristina ^d   Feusner, James H ^e   Gamis, Alan ^f   Gregory, John ^g   Larson, Richard A ^h   Powell, Bayard L ⁱ   Stock, Wendy ^h   Willman, Cheryl L ^j   Woods, William G ^k   Meshinchi, Soheil ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MAYO CLINIC CANCER CENTER   (United States)

^e CHILDREN S HOSPITAL OAKLAND   (United States)

^f CHILDREN S MERCY HOSPITAL   (United States)

^g Atlantic Health   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ WAKE FOREST SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^k CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

more..

Author keywords

Acute promyelocytic leukemia; APL; FLT3 mutation; Pediatric

Indexed keywords

FLT3 LIGAND;

ARTICLE; CANCER REGRESSION; CHILD; CLINICAL FEATURE; DEATH; DIAGNOSTIC PROCEDURE; FEMALE; GENE MUTATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RISK ASSESSMENT; SCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; INFANT; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTE COUNT; MALE; MUTATION; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84864945751     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24122     Document Type: Article

References (22)

1. Meshinchi S, Alonzo T, Stirewalt D, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006;108:3654-3661.
2. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-4335.
3. Kottaridis P, Gale R, Frew M, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-1759.
4. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000;96:3907-3914.
5. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434-2439.
6. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008;111:2776-2784.
7. Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008;111:1552-1559.
8. Shih L, Kuo M, Liang D, et al. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer 2003;98:1206-1216.
9. Au W, Fung A, Chim C, et al. FLT-3 aberrations in acute promyelocytic leukaemia: Clinicopathological associations and prognostic impact. Br J Haematol 2004;125:463-469.
10. Gale R, Hills R, Pizzey A, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 2005;106:3768-3776.
11. Kelly L, Kutok J, Williams I, et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002;99:8283-8288.
12. Le Beau MM, Davis EM, Patel B, et al. Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice identify cooperating events and genetic pathways to acute promyelocytic leukemia. Blood 2003;102:1072-1074.
13. Mathews V, Thomas M, Srivastava V, et al. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica 2007;92:994-995.
14. Callens C, Chevret S, Cayuela J, et al. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): A retrospective study from the European APL Group. Leukemia 2005;19:1153-1160.
15. Stock W, Najib K, Moser BK, et al. High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): Correlation with diagnostic features and treatment outcome (CALGB 9710). J Clin Oncol 2008;26: abstr 7002.
16. Yoo SJ, Park CJ, Jang S, et al. Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene. Leuk Lymphoma 2006;47:1788-1793.
17. Arrigoni P, Beretta C, Silvestri D, et al. FLT3 internal tandem duplication in childhood acute myeloid leukaemia: Association with hyperleucocytosis in acute promyelocytic leukaemia. Br J Haematol 2003;120:89-92.
18. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C971. Blood 2010;116:3751-3757.
19. Burnett A, Grimwade D, Solomon E, et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC trial. Blood 1999;93:4131-4143.
20. Sanz M, Lo Coco F, Martín G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000;96:1247-1253.
21. Marasca R, Maffei R, Zucchini P, et al. Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with flt3 mutational status. Leukemia 2006;20:103-114.
22. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. Lancet Oncol 2009;10:967-974.